Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report
27.3.2024 17:24:00 EET | Business Wire | Press release
PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report. A detailed overview of PCI’s multifaceted sustainability journey, the report showcases the strides taken from the program’s formal inception in 2021 through its 2023 fiscal year, and lays out ambitious goals for continued progress along multiple fronts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327397711/en/
The report discloses PCI's performance, targets, and strategy to achieve nine identified impact categories. (Photo: Business Wire)
The in-depth report discloses PCI's performance, targets, and strategy to achieve nine identified impact categories, from sustainability-focused practices concerning carbon footprint, responsible waste management and eco-conscious procurement to people-first issues such as health and safety, community impact and DEI. Given its position as a world-class CDMO whose global customers and vendors number well into the thousands, PCI’s ESG initiatives are intended to purposefully impact the many local and global communities it interacts with, cares for and serves.
True to this mindset, PCI Pharma’s ESG program is inherently inclusive and bottom-up. The report includes PCI’s approach to a Double Materiality Assessment, which gathers input from hundreds of employees as well as external stakeholders including customers, supplier partners, investors and community organizations. The purpose of this assessment is to identify those ESG elements important to and emphasized by all stakeholders and, from there, to focus on meaningful and measurable progress against those critical factors.
Encouragingly, the Double Materiality Assessment indicated that the majority of PCI’s ESG impact categories are in alignment with its stakeholders’ priorities. Even so, the assessment results were insightful and were taken into account to ensure long-term alignment between stakeholder priorities and PCI’s ESG strategy.
Other highlights from PCI’s ESG report include:
-
Emission reduction targets. By 2030, PCI aims to
- Reduce Scope 1 and 2 Greenhouse Gas emissions by 40%
- Cut its energy intensity by 50%
- Purchase 100% of its energy from renewable sources
Carbon footprint targets and strategy were developed in alignment to Science Based Targets. By 2045, PCI aims to achieve a Net-Zero carbon footprint across its entire supply chain.
- Water conservation. By 2030, PCI plans to reduce its global water consumption by 50% per cubic meter, and while the pharma sector’s cleanliness and sterility needs are inherently water-intensive, PCI remains committed to this ambitious goal.
- Waste management. By 2030, PCI targets non-hazardous waste intensity reduction by 33%, reduction of waste sent to landfills by 90%, and has plans in place to reach 100% recycling of recyclable waste.
* All environmental targets were calculated against a 2020 baseline.
- Community Impact. PCI has established a formal giving-back strategy focused on year-over-year increases in employee participation and measurable community impact for each of its global sites and corporate functions. Activities on this front include identifying the greatest needs of local communities and partnering with relevant organizations; communicating volunteer opportunities and encouraging employees to create interest groups; and a novel program called the ESG Day Initiative, in which employees can log up to eight hours per year of company-sponsored volunteer activities across various categories.
- Organization-wide DEI. PCI remains dedicated to enhancing our inclusion and diversity measurements, with a particular focus on pay equity and balanced gender and ethnic representation throughout the organization, extending to levels of executive and board leadership. The company’s DEI efforts extend beyond operations and into the supply chain; with the Supplier Diversity Program, PCI is increasing support for businesses owned by women, minorities and vulnerable groups in the supply chain.
A healthcare service company at its core, PCI sees its approach to ESG as showcasing how the wellbeing of the planet and its people are intimately interconnected.
“Although we at PCI formally established our ESG Program in 2021, our ESG consciousness is by no means new,” said Salim Haffar, CEO of PCI Pharma Services. “As a responsible business, we have been evolving daily to align our commitments, culture, and performance with the wellbeing of humans, the planet and the communities we serve. As a team, we are learning and adapting to industry best practices, sharing lessons learned along the way, and building a strong foundation for a resilient future.”
About PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain), and over 6,000 employees working to bring life-changing therapies to patients.
Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and commercialization. Its clients utilize PCI as an extension of their business, and a collaborative partner with the shared goal of improving patients’ lives. For more information, visit pci.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327397711/en/
Contact information
Christopher Dale
Turchette Agency
(973) 227-8080, ext. 116
cdale@turchette.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Yonder Announces New Leadership18.11.2026 15:03:00 EET | Press release
Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believe there is a significant additional opportunity to build on that solid foundation to expand the company’s software platform to help
AI Private Markets Platform FinBursa Appoints Angelica Tigan as Chief Revenue Officer to Drive US and Global Growth18.11.2026 15:00:00 EET | Press release
FinBursa, the intelligent front office for private markets, has appointed Angelica Tigan, a former BlackRock and eFront sales leader, as Chief Revenue Officer to lead its global commercial expansion following the launch of FinBursa 360. Based in the US, Tigan will lead sales and partnerships worldwide, with an immediate focus on the US. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118596329/en/ Angelica Tigan, based in New York City, joins FinBursa as Chief Revenue Officer Tigan brings close to two decades in private markets technology, having built, led and scaled sales teams at BlackRock (Aladdin) and eFront, with previous experience at Intralinks and Gen II Fund Services. FinBursa 360 is an all-in-one platform for private equity, private credit, real estate, venture capital and M&A advisory firms, family offices, wealth managers, placement agents and fund administrators. It brings investment CRM, deal flow and deal m
Scientist.com Launches Pharma Observatory, an Agent-First Market Intelligence Platform for Biopharma R&D18.11.2026 14:55:00 EET | Press release
Scientist.com, the leading AI-enabled R&D orchestration platform and marketplace for the life science industry, today announced the launch of Pharma Observatory, a market intelligence platform that shows biopharma teams where their programs sit in the wider market. Scientist.com helps research teams drive a project forward. Pharma Observatory places that project in context: who else is working on the same target or indication, who the likely partners and acquirers are, and what the eventual clinical trials are likely to look like. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118907460/en/ Scientist.com's Pharma Observatory brings nearly 1 billion records from ~100 public sources (ClinicalTrials.gov, FDA, USPTO, NIH, SEC) into one cross-referenced model. The public record on biopharma is huge but scattered. ClinicalTrials.gov, the FDA, SEC filings, PubMed, NIH, the USPTO and dozens of other sources each publish part of t
Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 14:36:00 EET | Press release
Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power. The funding will accelerate three areas of development: Helix HARUKA: Manufacturing and assembly of
New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 14:00:00 EET | Press release
Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the priorities and circumstances of each trip, rather than demographics alone. It calls on destinations and businesses to rethink how they attract visitors and measure success, shifting the focus from high-spending travelers to high-value trips that deliver meaningful experiences, support local economies and create lasting benefits for communities. “Travelers are not making decisions as fixed demographic segments. They are responding to purpose, pressures and possibilities of each trip,” said His Excellency Ahmed Al
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
